The future of the U.S. economy appears promising, with robust growth and strong corporate performance. This economic strength has propelled the stock market to record highs, signaling confidence in the economy’s resilience. The well established pharmaceutical industry continues to assert its economic dominance through resolute financials. In 2022, pharma stocks brought in $510.5 billion, with forecasts for the sector to reach $863.6 billion in revenue by 2030. Between 2023 and 2030, the industry is expected ...

AstraZeneca (AZN) announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab), for use in children. The regulatory body has now approved Fasenra as an add-on maintenance treatment for severe asthma in patients aged six to 11 years with an eosinophilic phenotype.Fasenra is already approved as an add-on maintenance treatment for severe eosinophilic asthma (SEA) in patients aged 12 and older.The latest approval for Fasenra was based on data from the open-label phase III TATE study, as ...

Stock Performance - Astrazeneca's stock ended at $69 45, marking a +1 97% increase from the previous day's close [1] - The stock outperformed the S&P 500, which gained 0 74%, while the Dow dropped 0 01% and the Nasdaq increased by 1 68% [1] - Over the past month, Astrazeneca's shares gained 0 78%, while the Medical sector lost 4 72% and the S&P 500 gained 0 8% [1] Earnings and Revenue Expectations - Astrazeneca is expected to report Q1 2024 EPS of $0 95, down 1 04% from the prior-year quarter [1] - Revenue for the quarter is expected to be $12 billion, a 10 27% increase compared to the year-ago quarter [1] - For the entire fiscal year, consensus estimates project earnings of $4 02 per share and revenue of $51 01 billion, representing year-over-year changes of +10 74% and +11 34%, respectively [2] Analyst Estimates and Valuation - Recent changes to analyst estimates reflect optimism about Astrazeneca's business and profitability [2] - The Zacks Consensus EPS estimate has moved 0 08% lower over the past month, and Astrazeneca currently holds a Zacks Rank of 3 (Hold) [3] - Astrazeneca is trading at a Forward P/E ratio of 16 95, a premium compared to its industry's average of 14 1 [3] - The company's PEG ratio is 1 25, lower than the industry average of 1 71 [3] Industry Overview - The Large Cap Pharmaceuticals industry, part of the Medical sector, holds a Zacks Industry Rank of 223, placing it in the bottom 12% of all industries [4] - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks within the groups [4]

AstraZeneca (AZN) and partner Daiichi Sankyo announced that the FDA has granted accelerated approval to their drug Enhertu for treating unresectable or metastatic HER2-positive solid tumors in heavily pretreated patients.The approval was based on data from the three phase II studies, including the DESTINY-PanTumor02 study on Enhertu, which showed clinically meaningful responses across a broad range of tumors. The accelerated approval was based on positive objective response rate (ORR) and duration of respon ...

AstraZeneca (AZN) announced positive data from the phase III ADRIATIC study, which evaluated its blockbuster cancer drug, Imfinzi (durvalumab), for treating patients with limited-stage small cell lung cancer (LS-SCLC), an aggressive form of lung cancer.The dual primary endpoints of this global phase III study are overall survival (OS) and progression-free survival (PFS).Data from the study showed that treatment with Imfinzi led to statistically significant and clinically meaningful improvement in the OS and ...

Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024.Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.Good afternoon! Drugmakers spent big on advertisements for weight loss and diabetes treatments last year as they wrestled for dominance in the booming market for those drugs. Companies spent more than $1 billion on ads for weight loss and diabetes medicines in 2023, up 51% from the prior year, according to new data fr ...

AstraZeneca (AZN) and partner Daiichi Sankyo announced that the FDA has accepted their biologics license application (BLA) seeking approval of the antibody drug conjugate, datopotamab deruxtecan (Dato-DXd), for a breast cancer indication.The BLA is seeking approval of Dato-DXd for treating unresectable or metastatic HR+ HER2- breast cancer in patients who have received prior systemic therapy for unresectable or metastatic disease.The FDA is expected to give its decision on the BLA in the first quarter of 20 ...

AstraZeneca (AZN) announced that the FDA had approved Voydeya (danicopan) for treating paroxysmal nocturnal hemoglobinuria (PNH), a rare and chronic blood disorder.Voydeya is a first-in-class oral Factor D inhibitor, which has been approved by the FDA as an add-on to standard-of-care C5 inhibitors, Ultomiris (ravulizumab) or Soliris (eculizumab), for the treatment of extravascular hemolysis in adult patients with PNH. Ultomiris and Soliris are also marketed by AstraZeneca for treating PNH and some other rar ...

In the latest trading session, Astrazeneca (AZN) closed at $67.25, marking a -0.74% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.2%. Meanwhile, the Dow lost 0.6%, and the Nasdaq, a tech-heavy index, added 0.11%.Prior to today's trading, shares of the pharmaceutical had gained 4.88% over the past month. This has outpaced the Medical sector's gain of 2.21% and the S&P 500's gain of 3.32% in that time.Investors will be eagerly watching for the performance of Ast ...

In my view, a sure-shot way of minting money from the markets is buying and holding with patience. Of course, the idea needs to be well-researched as a first step. An important point to note is that stocks can witness price or time correction. This column focuses on stagnating blue-chip stocks (time correction) that can awaken and surge higher.It’s not uncommon for investors to lose interest in stocks that have remained sideways for an extended period. That translates into undervaluation, and the stagnating ...